SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization.
The aim of this study was to develop and optimize SNEDDS formulations containing surfactants reported to be bioenhancers for improvement of dissolution and oral absorption of lacidipine (LCDP). Preliminary screening was carried out to select proper components combination. D-optimal mixture experimental design was applied to optimize a SNEDDS that contains a minimum amount of surfactant, a maximum amount of lipid, and possesses enhanced emulsification and dissolution rates. Three formulation variables; the oil phase X(1) (a mixture of Labrafil/Capmul), the surfactant X(2) (a mixture of Cremophor/Tween 80) and the co-surfactant X(3), were included in the design. The systems were assessed for droplet size, light absorbance, optical clarity, drug release and emulsification efficiency. Following optimization, the values of formulation components (X(1), X(2), and X(3)) were 34.20%, 40.41% and 25.39%, respectively. There is a good correlation between light absorbance and droplet size analysis of diluted SNEDDS (R(2)=0.883). Transmission electron microscopy demonstrated spherical droplet morphology. The stability of the optimized formulation was retained after storage at 40 degrees C/75% RH for three months. The optimized formulation of LCDP showed a significant increase in dissolution rate compared to the drug suspension under the same conditions. Our results proposed that the optimized SNEDDS formulation, containing bioenhancing surfactants, could be promising to improve oral absorption of LCDP.
Basalious
Emad B
EB
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-aini Street, Cairo 11562, Egypt. dremadbasalious@gmail.com
Shawky
Nevine
N
Badr-Eldin
Shaimaa M
SM
D000284:Administration, Oral; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004095:Dihydropyridines / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems / Q000379:methods; D004355:Drug Stability; D004655:Emulsions / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000737:chemistry; D008055:Lipids / Q000737:chemistry; D036103:Nanotechnology / Q000379:methods*; D010316:Particle Size; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry*
D004095:Dihydropyridines; D004655:Emulsions; D008055:Lipids; D013501:Surface-Active Agents; C060285:lacidipine